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Resonance-thrombography indices of the haemostatic process
in relation to risk of incident coronary heart disease: 9 years
follow-up in the Caerphilly Prospective Heart Disease Study
Coronary artery thrombosis plays a key role in the develop-
ment of coronary heart disease (CHD), and arterial thrombosis
has been described as ‘haemostasis in the wrong place’. The
haemostatic process involves the initial interaction of the
injured vessel wall with circulating platelets followed by
coagulation activation, resulting in the reduction of blood
flow by a platelet-fibrin haemostatic plug (in injured micro-
vessels) or a platelet-fibrin thrombus (in macro-vessels, for
example after rupture of an arterial atherosclerotic plaque).
The extent of fibrin formation is limited by activation of the
endogenous fibrinolytic system, which lyses fibrin to form
fibrin degradation products, such as fibrin d-dimer. These
processes are all influenced by blood flow, which is in turn
influenced by rheological and inflammatory variables inclu-
ding blood viscosity and white cell count.
Several studies have established that blood levels of several
haematological variables related to haemostasis and thrombo-
sis are associated with incident CHD. In the Caerphilly
Prospective Heart Disease Study in middle-aged men, we have
previously reported that incident CHD is associated with
plasma fibrinogen, plasma viscosity and with cell count
(Yarnell et al, 1991; Sweetnam et al, 1996), von Willebrand
factor (VWF) (Rumley et al, 1999) which, like fibrinogen is an
important mediator of platelet adhesion and aggregation,
coagulation Factor VIII (Rumley et al, 1999) and fibrin
d-dimer, a marker of activation of the coagulation and
fibrinolytic systems (Lowe et al, 1998) Tissue plasminogen
activator (t-PA) antigen and plasminogen activator inhibitor
(PAI-1) activity were assayed as other markers of the
fibrinolytic system (Lowe et al, 1998).
Measurement of these individual variables does not give an
adequate measure of the global interaction between platelets,
coagulation and fibrinolysis in the processes of haemostasis and
thrombosis. Global assays of these interactions include throm-
boelastography (TEG), which was introduced by Hartert, who
subsequently introduced flow stimulation into the clotting
process in resonance-thrombography (RTG) (Hartert, 1981,
1982). The latter measurement has been advocated for the
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Summary
Global assays, such as resonance-thrombography (RTG), which measure the
interaction between platelets, coagulation and fibrinolysis have been used as
summary measures of risk for over two decades but have not been evaluated
in epidemiological studies. We examined whether RTG indices are risk
indicators for incident coronary heart disease (CHD). RTG indices, related
haematological variables and other risk factors were measured between 1984
and 1988 in a cohort of 2398 British men. Reaction time (r) and amplitude of
fibrin leg (AF) were associated with lifestyle risk factors. During 9 years of
follow-up, 282 (12%) men developed a major new CHD event, as classified
by World Health Organization criteria. On adjustment for age, only r and AF
measured at baseline were related to risk of incident CHD. On multivariate
adjustment in a multiple logistic regression model that included age, diastolic
blood pressure, body mass index, total and high-density lipoprotein
cholesterol, lifestyle risk factors and use of prescribed medicine, these
associations weakened but remained significant. Additional adjustment for
fibrinogen, viscosity, white cell count and fibrin d-dimer either reduced these
associations to non-significance (AF) or to borderline significance (r).
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study, fibrinogen, blood coagulation.
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clinical laboratory screening of bleeding disorders (e.g. platelet
dysfunction, dysfibrinogenaemias, disseminated intravascular
coagulation and hyperfibrinolysis) (Hartert, 1981, 1982) but to
our knowledge has not been evaluated as a risk marker for
incident CHD in population-based prospective studies.
We therefore evaluated the association of four RTG indices
with incident CHD, conventional CHD risk factors, and other
haematological variables in the Caerphilly Prospective Heart
Disease Study. The objective of this study was to establish
whether or not these RTG indices were independently
associated with incident CHD.
Methods
The Caerphilly Collaborative Heart Disease Study began in
1979 with the overall objective of examining the determinants
and predictive ability of new and classical risk factors for
incident CHD. During the initial recruitment phase (1979–83)
2512 men aged 45–59 years were examined, representing 90%
of the population of men in this age group from the town of
Caerphilly, South Wales, UK, and its surrounding villages
(total population 40 000). Since then they have been examined
at 5-year intervals. At the first re-examination between 1984
and 1988, when the men were aged 49–64 years, men of the
same age who had moved into the defined geographical area
were also deemed to be eligible. A total of 2398 men were
recruited into the reconstructed cohort and they form the
baseline population for the current study.
The general design and methods of the Caerphilly Study
have been described elsewhere (Bainton et al, 1992; Sweetnam
et al, 1996). Briefly, at the survey between 1984 and 1988 the
men were invited to attend an afternoon/evening clinic where a
detailed medical and lifestyle history were obtained, the
London School of Hygiene and Tropical Medicine (LSHTM)
chest pain questionnaire (Rose et al, 1982) was administered, a
full 12-lead electrocardiogram (ECG) was recorded, and
height, weight and blood pressure were measured. Alcohol
consumption was obtained by the use of a self-administered
questionnaire checked at the clinic and converted from
standard units of volume to millilitres of pure alcohol per
week (Yarnell et al, 1983). Prescribed medication has been
shown previously to influence levels of haemostatic and
inflammatory markers (Yarnell et al, 2000, 2001) and was
included as a confounding variable. Only two subjects included
in this analysis were taking anticoagulants during the baseline
phase of this study (1984–88), and were classed among those
taking prescribed medication. The men were then invited to
return to an early morning clinic where a blood sample was
taken and a fasting blood sample was obtained from 2225 men
(93%).
Follow-up procedure and definition of incident CHD
The incidence of CHD was measured up to the third
re-examination of the men. In Caerphilly this took place
between 1993 and 1997 with a nearly constant interval of 105
(SD ¼ 6) months after the baseline, first re-examination. All
men had been flagged with the National Health Service Central
Registry and all death certificates were coded to the 9th
Revision of the International Classification of Diseases (ICD).
Fatal CHD was defined as any death coded to ICD 410-414
inclusive. At each re-examination, the LSHTM chest pain
questionnaire was re-administered and another ECG was
recorded. The LSHTM chest pain questionnaire was extended
to include questions about admission to hospital with severe
chest pain. These, together with lists from Hospital Activity
Analysis of all men admitted to local hospitals with a diagnosis
of ICD 410-414, were used as a basis for a search of hospital
notes for events satisfying World Health Organisation criteria
‘for definite non-fatal’ myocardial infarction (MI). Finally, the
appearance on any follow-up ECG of major or selected
moderate Q waves (Minnesota codes 1-1-any, 1-2-1 to 1-2-5 or
1-2-7) when there were no Q waves (1-1-any, 1-2-any or 1-3
any) on either the recruitment ECG or the baseline, first
re-examination ECG was taken as evidence that an MI had
occurred during the follow-up period.
Blood collection, storage and analysis
Blood was taken between 7.00 and 10.00 am for 91% of the
men, before 7.00 am for 7% and between 10.00 and 11.00 am
for 2%. The blood was collected without venous stasis into
evacuated containers using a 19-gauge butterfly needle and
Sarstedt monovette adapters (Leicester, UK). Various aliquots
were used for measurement of different haemostatic variables.
Citrated plasma
Measurements were made during 1994, when the plasma had
been stored at )70 for 6–10 years. Enzyme-linked immuno-
sorbent assays (ELISAs) were used for measurement of VWF,
d-dimer and t-PA as previously described (Lowe et al, 1998;
Rumley et al, 1999). PAI-1 activity was measured using a
chromogenic assay (Chromogenix, Stockholm, Sweden) (Lowe
et al, 1998). Clottable fibrinogen was later measured by an
automated Clauss assay in a Coag-A-Mate X 2 coagulometer
(Organon Teknika, Cambridge, UK) with the use of a separate
stored plasma sample (Sweetnam et al, 1998). One-third of
these samples had previously been used for another purpose,
so that a total of only 1378 samples was available.
EDTA plasma
Fresh dipotassium edentate-anticoagulated samples were used
to measure nephelometric fibrinogen, plasma viscosity and
white cell count as described previously (Yarnell et al, 1987,
1991). a2-Macroglobulin and a1-antitrypsin were measured
nephelometrically with Beckman antisera kits (High
Wycombe, UK). Lipid measures were made by using enzymatic
assays as described previously (Bainton et al, 1992).
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Resonance-thrombography
Resonance-thrombography is a successor to the technique of
thrombo-elastography (Hartert, 1981, 1982). RTG is a method
for measuring the start and progression of clot formation in
flowing blood, involving formation of elastic fibrin molecules
and their condensation by platelets. The resonance-thrombo-
graph consists of a cylinder suspended as a pendulum on an
elastic bar. The cylinder dips into a cylindrical container
heated to 37C. The 1Æ3 mm wide gap between them is filled
with 0Æ3–0Æ4 ml of citrated whole blood up to the container’s
rim. All measurements were made in the Department of
Haematology, Cardiff Royal Infirmary, by a dedicated techni-
cian within 7 h of collection of the samples. The action of this
measuring device consists of an orbital movement of the
cylinder within the container. The frequency of this electro-
magnetically forced movement is constant. The cylinder, by its
movement, encircles a tiny orbit. In the measuring procedure
the clot is subject to permanent strain by the orbital
movement. Its oscillation causes a stretching of fibrin mole-
cules and gives an assay of clot elasticity by recording a
differentiating resonance effect. The instrument used was
described in greater detail elsewhere (Hartert, 1982). The RTG
delivers distinguishable and characteristic types of graphs for
qualitative and quantitative differences in fibrin production
and similarly separate changes in platelet activity are recorded.
RTG parameters are shown in Fig 1. Reaction time (r)
measures the pre-phase of coagulation, f is the duration of
the ascending leg of the waveform mainly determined by the
growing fibrin structure – the fibrin time, AF is its amplitude.
Both f and r reflect clot formation, AF reflects the final clot
stiffness. The amplitude AP, representing the angle of the
platelet (P) leg, is mainly determined by platelet activity. In the
present study, r (min), f (min), AF (mm) and AP (mm) were
measured. To simplify its measurement, the amplitude of the
platelet leg (AP) was measured 300 s after maximum ampli-
tude (AF). Due to the shape and completeness of the trace it
was not always possible to measure this latter parameter, and
550 measurements could not be made for this reason.
Statistical methods
The distributions of RTG indices had a positive skew and all
were transformed to logarithms. For each, this transformation
produced a more nearly symmetrical Gaussian distribution
and stabilized variances. Comparisons of mean values between
men who developed major CHD and those who did not were
made by analysis of covariance (Nie et al, 1996).
Duplicate samples were assayed blindly by each laboratory
throughout the recruitment period. Coefficients of variation
were calculated for the RTG indices as follows: r ¼ 8Æ3%;
f ¼ 15Æ7%; AF ¼ 19Æ2% (all n ¼ 22); AP ¼ 22Æ7% (n ¼ 13).
Evidence of ischaemia at baseline was assessed from the
chest pain questionnaire and the ECG. Three categories,
namely angina, history of at least one episode of prolonged,
severe chest pain and ECG ischaemia were defined as reported
previously (Bainton et al, 1988). Among the cohort of 2398
men, 736 (31%) had some evidence of ischaemia at baseline.
This was similar to the prevalence found by the British
Regional Heart Study (Shaper et al, 1984) for men of a similar
age. Exclusion of such a large group, among whom almost half
of the incident events occurred, did not seem satisfactory.
Neither did the usual practice of excluding just a very small
percentage (usually <5%) of men for whom there is good
clinical evidence of a previous MI. Instead, we have chosen to
include all men and to adjust for the presence of ischaemia at
baseline by including this as a confounder in the logistic
regression analyses with the occurrence, or not, of a major
incident CHD event as the binary dependent variable (Yu et al,
2003). The distributions of RTG indices were divided into
Fig 1. Resonance-thrombography: derivation of
the four indices.
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equal ‘thirds’ and the results were presented as the relative
odds of major incident CHD in each ‘third’, relative to a
baseline ‘third’, which was always taken as the 33% of men
with the lowest levels, with adjustment for age and other risk
factors. These were referred to throughout as relative odds and
where appropriate they were shown together with 95%
confidence intervals (CI) estimated from the logistic regression
models. Standardized relative odds were calculated as sum-
mary measures (the proportionate change in relative odds
associated with standard deviation change in the RTG index).
Results
Of the total cohort of 2398 British men, 282 (11Æ8% of all men)
developed major new CHD events over the follow-up period of
nearly 9 years. Of these 282, 132 (46Æ8%) were fatal and 150
were non-fatal (53Æ2%). Fasting blood samples were available
from 2225 (93%) men; of these, 261 (11Æ7%) developed major
new CHD. Results for RTG indices were available for up to
1491 (67%) of fasting men, of whom 176 (11Æ8%) developed
new major CHD. Common results were available for 1470 men
for r, f and AF and 920 for AP; which was unavailable for a
larger number of subjects as a delay of five additional minutes
was required for its measurement.
Table I shows the geometric mean of RTG indices according
to smoking status, social class, history of diabetes, work activity,
prescribed medicine, family history of CHD and pre-existing
CHD at baseline. The mean level of r was significantly different
between manual and non-manual social class (P ¼ 0Æ002). For
AF, there were also significant differences between non-smok-
ers, ex-smokers and current smokers (P ¼ 0Æ018), between
manual and non-manual social class (P ¼ 0Æ001) and between
subjects with and without prescribed medicine (P ¼ 0Æ003).
Table II shows the Pearson correlation coefficients between
RTG indices and some indicators of CHD risk. Even low
correlations achieved statistical significance because of the
large number of subjects in the study but only correlations in
excess of 0Æ1 would be likely to have any biological relevance;
Table I. Geometric mean of RTG indices
according to smoking status, social class, history
of diabetes, work activity, prescribed medicine,
family history of CHD and pre-existent CHD at
baseline between 1984 and 1988 in men from
Caerphilly, South Wales, UK.
r (min)+ f (min)+ AF (mm)+ AP(mm)+
Smoking status
Nonsmoker 6Æ69 2Æ41 18Æ17 2Æ94
Ex-smoker 6Æ75 2Æ38 16Æ93 2Æ91
Current smoker 6Æ82 2Æ37 16Æ63 3Æ00
Test of difference++ 0Æ474 0Æ771 0Æ018* 0Æ653
Social class
Manual 6Æ86 2Æ39 16Æ53 2Æ94
Non-manual 6Æ60 2Æ36 17Æ94 2Æ99
Test of difference++ 0Æ002** 0Æ450 0Æ001*** 0Æ587
History of diabetes
Yes 7Æ08 2Æ33 15Æ51 3Æ20
No 6Æ76 2Æ38 17Æ04 2Æ95
Test of difference++ 0Æ178 0Æ628 0Æ155 0Æ320
Work activity
High 6Æ81 2Æ39 16Æ81 2Æ92
Low 6Æ72 2Æ36 17Æ28 3Æ00
Test of difference++ 0Æ266 0Æ356 0Æ235 0Æ381
Prescribed medicine
Yes 6Æ83 2Æ37 16Æ40 2Æ94
No 6Æ71 2Æ39 17Æ53 2Æ96
Test of difference++ 0Æ124 0Æ647 0Æ003** 0Æ811
Family history of CHD
Yes 6Æ74 2Æ37 17Æ48 2Æ92
No 6Æ77 2Æ38 16Æ92 2Æ96
Test of difference++ 0Æ802 0Æ819 0Æ347 0Æ728
Evidence of CHD at baseline
Yes 6Æ79 2Æ42 16Æ93 2Æ93
No 6Æ76 2Æ36 17Æ02 2Æ97
Test of difference++ 0Æ789 0Æ219 0Æ830 0Æ657
RTG, resonance-thrombography; CHD, coronary heart disease; r, reaction time; f, fibrin for-
mation time; AF, amplitude of fibrin leg; AP, amplitude of presenting the angle of platelet leg.
+Values are geometric mean.
++Values are P-values by one-way analysis of variance. All RTG indices are logarithmically
transformed.
Significantly different at *0Æ05, **0Æ01 and ***0Æ001.
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r was positively associated with nephelometric and clottable
fibrinogen and plasma viscosity; f was positively associated
with haemoglobin, and was negatively associated with
d-dimer, VWF antigen, nephelometric and clottable fibrinogen
and plasma viscosity. AF was negatively associated with age,
total cholesterol, d-dimer, nephelometric and clottable fibrin-
ogen, plasma and serum viscosity, white cell count, and
a1-antitrypsin. AP was negatively associated with clottable
fibrinogen and haemoglobin. The strongest correlations were
between AF and inflammatory and rheological markers, such
as the two measurements of fibrinogen and plasma viscosity.
Table III shows the mean, median and geometric mean for
RTG indices in men who developed CHD, and men who did
not. The mean difference was statistically significant between
subjects with and without incident CHD only for AF by
analysis of covariance after adjustment for age (P ¼ 0Æ003);
but also approached statistical significance for r (P ¼ 0Æ057).
Logistic regression models were used to analyse the relation
of RTG indices to the risk of incident CHD. Table IV shows
the results of relative odds and 95% CI for major incident
CHD events. Also shown are the standardized relative odds
(SRO) – the proportionate change in relative odds associated
with an increase of 1 standard deviation in the RTG indices.
After adjustment for age, r was a predictor of risk of incident
CHD; relative odds with increasing tertile categories, when
compared with the lowest third category, were 2Æ22 (95% CI,
1Æ41–3Æ50) and 1Æ87 (95% CI, 1Æ19–2Æ93), respectively. Partici-
pants in the second and third tertile group showed a 122% and
Table II. Pearson correlation coefficients between
RTG indices and indicators of CHD risk. Variables r (min) f (min) AF (mm) AP (mm)
Age (years) 0Æ057* )0Æ048 )0Æ146** )0Æ040
Body mass index (kg/m2) )0Æ022 )0Æ011 )0Æ031 )0Æ040
Diastolic blood pressure (mmHg) 0Æ003 0Æ002 0Æ003 )0Æ013
Systolic blood pressure (mmHg) 0Æ015 )0Æ053* )0Æ053* )0Æ038
Alcohol consumption+ (ml/week of pure alcohol) )0Æ026 0Æ075** 0Æ060* 0Æ024
Total cholesterol (mmol/l) 0Æ046 )0Æ015 )0Æ104** )0Æ082*
HDL cholesterol (mmol/l) )0Æ049 )0Æ035 0Æ094** )0Æ016
Triglycerides (mmol/l)+ )0Æ007 0Æ009 )0Æ041 )0Æ017
d-dimer (ng/ml)+ 0Æ077** )0Æ175** )0Æ258** )0Æ024
von Willebrand factor (IU/dl)+ )0Æ032 )0Æ117** )0Æ073** 0Æ043
Tissue plasminogen activator (ng/ml)+ )0Æ012 0Æ024 )0Æ080** )0Æ055
Plasminogen activator inhibitor (% pool)+ )0Æ069** 0Æ003 )0Æ034 )0Æ020
Nephelometric fibrinogen (g/L)+ 0Æ202** )0Æ153** )0Æ488** )0Æ021
Plasma viscosity (mPa s)+ 0Æ145** )0Æ179** )0Æ406** )0Æ048
White cell count (109/l)+ 0Æ092** )0Æ066* )0Æ220** )0Æ080*
Clottable fibrinogen (g/l)+ 0Æ183** )0Æ281** )0Æ498** )0Æ114**
Serum viscosity (mPa s)+ 0Æ087** )0Æ083** )0Æ202** )0Æ022
Haemoglobin (g/dl)+ 0Æ031 0Æ314** 0Æ094** 0Æ165**
Gamma glutamyl transferase (IU/l)+ )0Æ053* 0Æ001 )0Æ070** 0Æ008
a2-macroglobulin (mg/dl)+ 0Æ056* )0Æ030 )0Æ099** )0Æ004
a1-antitrypsin (mg/dl)+ 0Æ024 )0Æ096** )0Æ164** )0Æ060
HDL, high-density lipoprotein.
*P < 0Æ05, **P < 0Æ01.
+Values of the variable are logarithmically transformed.
Abbreviations as in Table I.
Table III. Mean, median and geometric mean for RTG indices in men who developed CHD, and men who did not during 9 years follow-up.
Incident CHD Free of incident CHD
Mean difference+ P-valueNo. Mean (SD) Median GM No. Mean (SD) Median GM
r (min) 172 7Æ10 (1Æ20) 7Æ00 6Æ99 1298 6Æ91 (1Æ52) 7Æ00 6Æ74 0Æ035 (0Æ018) 0Æ057
f (min) 172 2Æ48 (0Æ67) 2Æ50 2Æ38 1298 2Æ51 (0Æ91) 2Æ50 2Æ38 0Æ001 (0Æ026) 0Æ956
AF (mm) 172 16Æ83 (6Æ90) 16Æ00 15Æ35 1298 18Æ71 (7Æ33) 18Æ00 17Æ22 )0Æ106 (0Æ035) 0Æ003
AP (mm) 113 3Æ29 (1Æ60) 3Æ00 2Æ98 807 3Æ28 (1Æ88) 3Æ00 2Æ95 0Æ014 (0Æ044) 0Æ746
SD, standard deviation; GM, geometric mean.
+Values are adjusted-age mean difference (logarithmic scale) and standard error.
++The significant test between subjects with and without incident CHD by analysis of covariance; the tests were adjusted for age.
Abbreviations as in Table I.
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87% increase in risk in 9-year incidence of CHD, respectively.
After adjusting the data additionally for age and other risk
factors listed in Table IV, the relative odds were 2Æ17 (95% CI,
1Æ35–3Æ47) and 1Æ72 (95% CI, 1Æ07–2Æ76) respectively; men in
the second and third tertile group showed a 117% and 72%
increase in risk. After additional adjustment for
d-dimer antigen, plasma viscosity, nephelometric fibrinogen
and white cell count, men in the second and third tertile group
still showed increases in risk. But the tests for trend that were
summarized by SROs were not significant, either after
multivariate adjustment, or after adjustment for additional
haematological variables.
A similar analysis was carried out for AF. After adjustment
for age, relative odds with increasing tertile groups, when
compared with the lowest tertile group, were 0Æ80 (95% CI,
0Æ55–1Æ5) and 0Æ56 (95% CI, 0Æ37–0Æ84); men in the lowest
tertile group showed a 44% reduction in risk. After adjusting
the data additionally for age and other risk factors, the relative
odds were 0Æ86 (95% CI, 0Æ59–1Æ27) and 0Æ64 (95% CI,
0Æ41–0Æ98), respectively; men in the lowest tertile group
showed a 36% reduction in risk. But the tests for trend were
not significant, either after multivariate adjustment or after
adjustment for additional haematological variables.
Discussion
We have shown for the first time in a prospective study that
two of the four RTG indices were associated with incident
CHD. Men with incident CHD had a longer initial reaction
time (r index; P ¼ 0Æ057 on univariate analysis). The ampli-
tude of fibrin formation (AF) was also significantly shorter in
men who subsequently developed incident CHD than in men
who did not (P ¼ 0Æ003 on univariate analysis). The two other
parameters studied did not show a significant association with
incident CHD.
In general, classical CHD risk factors showed weak associ-
ations with RTG indices. Smoking, manual social class and use
of prescribed medicine were associated with shorter AF index
(Table I), as were age, systolic blood pressure and cholesterol
(Table II). In contrast, haematological risk predictors including
fibrinogen, plasma and serum viscosity, and fibrin d-dimer
were strongly associated with shorter AF index, and longer
reaction time (r index; Table II). These findings are consistent
with previous reports for fibrinogen and its degradation
products (Hartert, 1981, 1982; Zuckerman et al, 1981).
Increasing fibrinogen levels delay the onset of clot formation
by inhibiting the rate of fibrin polymerization (Blomback et al,
1989) and produce denser fibrin clots (Lim et al, 2003).
Adjustment for classical CHD risk factors reduced the
associations of RTG indices with incident CHD to borderline
statistical significance (Table IV), while the additional adjust-
ment for haematological risk predictors, including fibrinogen
and white cell count (Danesh et al, 1998), plasma viscosity
(Danesh et al, 2000) and fibrin d-dimer (Danesh et al, 2001)
reduced these associations further, especially for AF index
(Table IV). We therefore conclude that RTG indices did not
add significantly to the multivariate prediction of CHD risk in
the present study. Further, larger studies are required to
Table IV. Age and multivariate-adjusted relat-
ive odds (95% CI) of incident CHD by thirds of




1 2 3 SRO++
r (min)+ 1Æ00 2Æ22 (1Æ41, 3Æ50)*** 1Æ87 (1Æ19, 2Æ93)** 1Æ19 (91Æ00, 1Æ41)*
1Æ00 2Æ17 (1Æ35, 3Æ47)*** 1Æ72 (1Æ07, 2Æ76)* 1Æ16 (0Æ97, 1Æ39)
1Æ00 2Æ12 (1Æ26, 3Æ55)** 1Æ77 (1Æ05, 2Æ98)* 1Æ15 (0Æ93, 1Æ41)
f (min)+ 1Æ00 1Æ00 (0Æ67, 1Æ48) 1Æ04 (0Æ71, 1Æ52) 1Æ01 (0Æ86, 1Æ18)
1Æ00 1Æ13 (0Æ75, 1Æ71) 1Æ16 (0Æ78, 1Æ74) 1Æ06 (0Æ90, 1Æ26)
1Æ00 1Æ32 (0Æ84, 2Æ08) 1Æ49 (0Æ94, 2Æ35) 1Æ19 (0Æ98, 1Æ44)
AF (mm)+ 1Æ00 0Æ80 (0Æ55, 1Æ15) 0Æ56 (0Æ37, 0Æ84)** 0Æ80 (0Æ69, 0Æ93)**
1Æ00 0Æ86 (0Æ59, 1Æ27) 0Æ64 (0Æ41, 0Æ98)* 0Æ88 (0Æ75, 1Æ04)
1Æ00 0Æ93 (0Æ60, 1Æ45) 0Æ80 (0Æ48, 1Æ33) 0Æ98 (0Æ80, 1Æ20)
AP (mm)+ 1Æ00 0Æ82 (0Æ50, 1Æ35) 1Æ04 (0Æ66, 1Æ66) 1Æ04 (0Æ85, 1Æ26)
1Æ00 0Æ82 (0Æ49, 1Æ37) 1Æ13 (0Æ70, 1Æ83) 1Æ08 (0Æ88, 1Æ33)
1Æ00 0Æ77 (0Æ43, 1Æ36) 1Æ19 (0Æ71, 2Æ01) 1Æ14 (0Æ90, 1Æ45)
CI, confidence interval; SRO, standardized relative odds.
+First row indicates age-adjusted relative odds and 95% CI; second row indicates multivariate-
adjusted relative odds and 95% CI; third row indicates additional adjustment for d-dimer
antigen, plasma viscosity, nephelometric fibrinogen and white cell count.
Adjusted multiple variables are age, diastolic blood pressure, body mass index, smoking habit,
alcohol consumption, social class, prescribed medicine, total cholesterol and HDL cholesterol.
++Standardized relative odds are the proportionate change in relative odds associated with an
increase of 1 standard deviation in the RTG index level.
Significantly different at *0Æ05, **0Æ01 and ***0Æ001.
Abbreviations as in Table I.
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determine with confidence the size of their associations with
CHD risk and their use (if any) in CHD risk prediction.
Our results suggest that the association of some classical
CHD risk factors (e.g. smoking) (Yarnell et al, 1987) as well as
some haematological variables, with CHD risk (Danesh et al,
1998, 2000, 2001) may be partly attributable to their effects on
the clotting of flowing blood in vitro, and hence potentially on
coronary thrombus formation in vivo. Further experimental
work is required to test these hypotheses – for example the
effect of smoking reduction or cessation on RTG indices.
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